The Ten Bagger Quest
Small pharma targets multi £billion market
By Michael Crockett
It has been quite a while since AimZine cast its net in search of a share with “multi-bagger” potential. But right now there appears to us to be a number of lowly rated microcaps that could one day be big winners. So, over the coming weeks, we will be sharing these opportunities with readers.
For today’s article we look at a small pharmaceutical company that has recently reported some very encouraging results from drug trials for its lead compound. The Company is targeting a huge multi-billion pound marketplace. But is it all a pipe dream or is the opportunity real? - AimZine reports on some very positive signs.
Verona Pharma (AIM: VRP) http://www.veronapharma.com/ Introduction Verona is a UK-based pharmaceutical Company which is focused on developing its lead compound, RPL554, to treat COPD (Chronic Obstructive Pulmonary Disease), asthma and cystic fibrosis. The Company is listed on AIM and at a share price of 3.5 pence has a market capitalisation on £34 million. Verona Pharma joined AIM in 2006. At that time the Company, originally named Isis Resources, purchased Rhinopharma, a private Canadian company whose assets included RPL554. Clinical Trial Success RPL554 is an inhaled drug which acts both as a bronchodilator* and an anti-inflammatory. Verona claim that this dual…